ABUS vs GD · P/E 5.4, rev $6.2M vs P/E 22, rev $52.55B
Arbutus Biopharma Corp (ABUS) versus General Dynamics Corporation (GD) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
General Dynamics Corporation (GD) is a aerospace & defense company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GD revenue for 2025-12-31 was $52.55B. Net income was $4.21B. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. GD currently screens at market cap $93.69B and trailing P/E 21.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GD currently screens at market cap $93.69B and trailing P/E 21.8.
Not investment advice. Open the ABUS and GD stock pages for the full models.
Not investment advice.